

Supplementary Materials




Figure S1. (A) Detection of SARS-CoV-2 RBD- and S1-specific IgM and IgA antibodies in the study participants' plasma. A total of thirty pre-pandemic patient samples [22] served as control. Results are represented by the OD units of each isotype, adjusted to the cut-off value of each individual plate and then normalized to the cut-off, which was set as one. The cut-off was determined by the mean OD + 2SD of the pre-pandemic samples. All samples were normalized to the cut-off value, which was set as one and is indicated by a dotted line. (B) The correlation between IgG and IgA (left panel) as well as IgG and IgM (right panel) responses to RBD SARS-CoV-2 antigens and (C) between IgG and IgA (left panel) as well as IgG and IgM (right panel) responses to S1 SARS-CoV-2 antigens. Statistical analyses were performed using a non-parametric Spearman Rank correlation.

Table S1. Univariate analysis comparing the distribution of IgG, IgA and IgM responses to SARS-CoV-2 S1 and RBD antigens in the entire patient cohort ($n = 150$) based on the definition of IgG seroconversion, which was set at 2SD above the mean optical density of 30 pre-pandemic samples [22] for each plate. All OD values to IgM and IgA RBD and S1 were normalized to plate cut-off and defined as positive if >2SD mean optical density of the pre-pandemic samples. Data are presented as number and percentage of total or median and range as appropriate. P -values are by Mann-Whitney test for continuous variables or Fisher's Exact test for categorical variables as appropriate. $p < 0.05$ is considered significant and indicated with *.

		SARS-CoV-2 Antibody Negative ($n = 44$) N (%) or Median (Range)	SARS-CoV-2 Antibody Positive ($n = 106$) N (%) or Median (range)	p -Value
RBD IgG, OD		0.71 (0.16–0.96)	1.25 (0.47–7.09)	<0.001 *
RBD IgG	negative	44 (100.0%)	30 (28.3%)	<0.001 *
	positive	0 (0.0%)	76 (71.7%)	
RBD IgM, OD		0.57 (0.15–2.29)	0.67 (0.18–2.34)	0.032 *
RBD IgM	negative	38 (86.4%)	75 (70.8%)	0.043 *
	positive	6 (13.6%)	31 (29.2%)	
RBD IgA, OD		0.74 (0.21–1.98)	0.93 (0.22–2.82)	0.002 *
RBD IgA	negative	34 (77.3%)	59 (55.7%)	0.013 *
	positive	10 (22.7%)	47 (44.3%)	
S1 IgG, OD		0.72 (0.15–0.98)	1.83 (0.29–6.44)	<0.001 *
S1 IgG	negative	44 (100.0%)	8 (7.5%)	<0.001 *
	positive	0 (0.0%)	98 (92.5%)	
S1 IgM, OD		0.56 (0.20–2.50)	0.67 (0.15–2.49)	0.028 *
S1 IgM	negative	36 (81.8%)	75 (70.8%)	0.16
	positive	8 (18.2%)	31 (29.2%)	
S1 IgA, OD		0.64 (0.08–3.09)	1.08 (0.11–4.90)	<0.001 *
S1 IgA	negative	36 (81.8%)	49 (46.2%)	<0.001 *
	positive	8 (18.2%)	57 (53.8%)	

Table S2. Univariate analysis comparing self-reported symptoms at presentation between patients who were negative ($n = 44$) and positive ($n = 106$) for SARS-CoV-2 antibodies. SARS-CoV-2 antibody positivity was detected by ELISA to IgG RBD and S1 ("Negative" indicates that a patient sample had an OD value below the assay cut-off for both IgG RBD and S1 ELISAs). Data are presented as number and percentage of total. Participants with missing data are excluded per characteristic. p -values are by Fisher's Exact test. $p < 0.05$ is considered significant.

		SARS-CoV-2 Antibody Negative ($n = 44$) N (%) or Median (Range)	SARS-CoV-2 Antibody Positive ($n = 106$) N (%) or Median (Range)	p -Value
Other co-infection	No	42 (95.5%)	99 (97.1%)	0.638
	Yes	2 (4.5%)	3 (2.9%)	
Fever	No	44 (100.0%)	103 (98.1%)	1.00
	Yes	0 (0.0%)	2 (1.9%)	
Fatigue	No	43 (97.7%)	101 (96.2%)	1.00
	Yes	1 (2.3%)	4 (3.8%)	
Edema	No	42 (95.5%)	100 (96.2%)	1.00
	Yes	2 (4.5%)	4 (3.8%)	
Cachexia	No	42 (97.7%)	99 (96.1%)	1.00
	Yes	1 (2.3%)	4 (3.9%)	
Respiratory symptoms	No	44 (100.0%)	95 (94.1%)	0.178
	Yes	0 (0.0%)	6 (5.9%)	

Gastrointestinal disturbance	No	42 (97.7%)	101 (98.1%)	1.00
	Yes	1 (2.3%)	2 (1.9%)	
Arthralgia	No	40 (97.6%)	87 (94.6%)	0.666
	Yes	1 (2.4%)	5 (5.4%)	
Altered mental state	No	43 (97.7%)	102 (97.1%)	1.00
	Yes	1 (2.3%)	3 (2.9%)	
Neuropathy	No	42 (100.0%)	102 (97.1%)	0.558
	Yes	0 (0.0%)	3 (2.9%)	
Radiographic abnormalities	No	44 (100.0%)	104 (100.0%)	1.00
	Yes	0 (0.0%)	0 (0.0%)	
Coughing	No	42 (100.0%)	98 (93.3%)	0.192
	Yes	0 (0.0%)	7 (6.7%)	
Loss of weight	No	40 (95.2%)	95 (90.5%)	0.510
	Yes	2 (4.8%)	10 (9.5%)	
Night sweats	No	41 (95.3%)	98 (93.3%)	1.00
	Yes	2 (4.7%)	7 (6.7%)	
Overall symptoms at presentation	No	39 (88.6%)	80 (75.5%)	0.079
	Yes	5 (11.4%)	26 (24.5%)	